HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.
May 06, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics maintains a Buy rating and a $9 price target from HC Wainwright & Co., indicating strong analyst confidence.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to an uptick in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100